mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma

A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer

(2016) Masanori Noguchi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

(2016) Sofie Wilgenhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma

(2016) Katherine Woods et al.   Journal for ImmunoTherapy of Cancer

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment

(2015) Frauke M. Schnorfeil et al.   Journal of Hematology & Oncology

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

(2015) S. Van Lint et al.   Cancer Immunology Research

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

(2015) Kalijn F Bol et al.   OncoImmunology

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology

(2014) Mads Hald Andersen   IMMUNOLOGIC RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response

(2014) Genevieve M Weir et al.   OncoImmunology

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

(2013) S. Munir et al.   CANCER RESEARCH

IL-12p70–producing patient DC vaccine elicits Tc1-polarized immunity

(2013) Beatriz M. Carreno et al.   JOURNAL OF CLINICAL INVESTIGATION

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

(2013) S M Ahmad et al.   LEUKEMIA

Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells

(2013) Amandine Legat et al.   Frontiers in Immunology

Rational combinations of immunotherapeutics that target discrete pathways

(2013) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production

(2012) J. C. Riches et al.   BLOOD

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

(2012) Eva Ellebaek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

(2012) E. H. J. G. Aarntzen et al.   CLINICAL CANCER RESEARCH

Cellular Based Cancer Vaccines: Type 1 Polarization of Dendritic Cells

(2012) M. Hansen et al.   CURRENT MEDICINAL CHEMISTRY

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

(2012) Eva Ellebaek et al.   Journal of Translational Medicine

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

(2012) CHIE OSHITA et al.   ONCOLOGY REPORTS

Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma

(2011) Sofie Wilgenhof et al.   JOURNAL OF IMMUNOTHERAPY

High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer

(2010) Özcan Met et al.   BREAST CANCER RESEARCH AND TREATMENT

Response definition criteria for ELISPOT assays revisited

(2010) Z. Moodie et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

(2010) Redas Trepiakas et al.   CYTOTHERAPY

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

(2010) Antoni Ribas et al.   Journal of Translational Medicine

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

(2009) A. Ribas et al.   CLINICAL CANCER RESEARCH

Inhibitory Effect of RNA Pool Complexity on Stimulatory Capacity of RNA-pulsed Dendritic Cells

(2009) Miran Javorovic et al.   JOURNAL OF IMMUNOTHERAPY

Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma

(2008) Annika Berntsen et al.   JOURNAL OF IMMUNOTHERAPY

Studies on mRNA Electroporation of Immature and Mature Dendritic Cells: Effects on their Immunogenic Potential

(2008) Özcan Met et al.   MOLECULAR BIOTECHNOLOGY